ArticleFrontiers in aging2023
Identification of dihydromyricetin as a natural DNA methylation inhibitor with rejuvenating activity in human skin.
Article in Frontiers in aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 23 citations in OpenAlex.
- Facial skin aging: an integrative analysis of genetics, epigenetics, and lifestyle factors.GeroScience · 2026Article
- Dihydromyricetin-LoadedPharmaceutics · 2026Article
- A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.Aging cell · 2026Review
- Epigenetic dynamics of cellular senescence: From mechanistic insights to precision senotherapy.Chinese medical journal · 2026Review
- Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist-Related Facial Aging.The Journal of clinical and aesthetic dermatology · 2026Article
- Skin aging: mechanisms, evaluation, and rejuvenation.The EMBO journal · 2026Review
- Non-ablative fractional laser 1940-nm treatment modulates epigenetic signatures associated with skin aging in a split-face investigation.Scientific reports · 2026Article
- Advances in skin aging: integrating epigenetic, cellular, and immune mechanisms for targeted therapy.Immunity & ageing : I & A · 2026Review
- Epigenetic Skin Aging and Its Reversal to Improve Skin Longevity across Ethnicities and Phototypes Using a Dihydromyricetin-Containing Serum: Results from a Prospective, Single-Cohort Study.Dermatology and therapy · 2026Article
- Unraveling the complexity of skin's biological aging utilizing epigenetic clocks.Clinical epigenetics · 2026Article
- A State-of-the-Art Overview on (Epi)Genomics and Personalized Skin Rejuvenating Strategies.Pharmaceutics · 2025Review
- Unlocking Longevity in Aesthetic Dermatology: Epigenetics, Aging, and Personalized Care.International journal of dermatology · 2025Review
- Epigenetic Regulation of Aging and its Rejuvenation.MedComm · 2025Review
- Systemic factors in young human serum influenceAging · 2025Article
- Advances in Longevity: The Intersection of Regenerative Medicine and Cosmetic Dermatology.Journal of cosmetic dermatology · 2025Review
- Dihydromyricetin May Attenuate Skin Aging as a RAGE Inhibitor.Nutrients · 2025Article
- Epigenetic Clocks in Skin Aging: From Exposome Drivers to Biomarkers and Therapeutic Interventions.Clinical, cosmetic and investigational dermatology · 2025Review
- Advances in the application of multi-omics analysis in skin aging.Frontiers in aging · 2025Review
- Predictive Biomarkers: A New Frontier in Bespoke Aesthetic Dermatology.Aesthetic surgery journal. Open forum · 2025Article
- Longevity cosmeceuticals as the next frontier in cosmetic innovation: a scientific framework for substantiating product claims.Frontiers in aging · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in DNA methylation patterning have been reported to be a key hallmark of aged human skin. The altered DNA methylation patterns are correlated with deregulated gene expression and impaired tissue functionality, leading to the well-known skin aging phenotype. Searching for small molecules, which correct the aged methylation pattern therefore represents a novel and attractive strategy for the identification of anti-aging compounds. DNMT1 maintains epigenetic information by copying methylation patterns from the parental (methylated) strand to the newly synthesized strand after DNA replication. We hypothesized that a modest inhibition of this process promotes the restoration of the ground-state epigenetic pattern, thereby inducing rejuvenating effects. In this study, we screened a library of 1800 natural substances and 640 FDA-approved drugs and identified the well-known antioxidant and anti-inflammatory molecule dihydromyricetin (DHM) as an inhibitor of the DNA methyltransferase DNMT1. DHM is the active ingredient of several plants with medicinal use and showed robust inhibition of DNMT1 in biochemical assays. We also analyzed the effect of DHM in cultivated keratinocytes by array-based methylation profiling and observed a moderate, but significant global hypomethylation effect upon treatment. To further characterize DHM-induced methylation changes, we used published DNA methylation clocks and newly established age predictors to demonstrate that the DHM-induced methylation change is associated with a reduction in the biological age of the cells. Further studies also revealed re-activation of age-dependently hypermethylated and silenced genes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.